|
Source – The Medicines and Healthcare Regulatory Agency (MHRA) - The MHRA is to look into the health risks and benefits of Strattera
®
, a prescription-only medicine used to treat attention deficit hyperactivity disorder (ADHD). This follows new clinical trial data which identified an increased risk of suicidal thoughts and behaviour in children treated with Strattera®.
Strattera® is not extensively used in the United Kingdom for the treatment of ADHD, but patients together with parents and
guardians are being advised of the risk and should be made aware of any possible signs and symptoms.
To view the press release go to:
http://www.mhra.gov.uk/news/press_Strattera_290905.pdf
Prepared by Susan Wileman Medicines Information Technician
Date of Preparation: 30th September 2005
|
